期刊文献+

瑞加德松的全合成研究 被引量:1

Total synthesis of regadenoson
下载PDF
导出
摘要 目的:改进瑞加德松的合成工艺,提高收率与质量,获得良好的生产工艺。方法:以2-氯腺苷的羟基为原料,经叔丁基二甲基硅烷保护,与水合肼反应得2’,3’,5’-三叔丁基二甲基硅氧基-2-肼基腺苷,再和2-甲酰基-3-氧代丙酸乙酯环合后经甲胺化得带保护的瑞加德松,最后脱去保护基得到瑞加德松。结果 :产品纯度和收率分别提高到99.0%和47.2%。结论 :优化后工艺收率高,产品质量好,操作简便,适合工业化生产。 Objective: To improve the process for the synthesis ofregadenoson and its quality. Methods: Regadenoson was synthesized from 2-chloroadenosine via etherification with t-butyldimethylchlorosilane, reaction with hydrazine hydrate to give 2',3',5'-tri-(tert-butyldimethylsiyl)oxy-2-hydrazinyl adenosine, which was cyclized with ethyl 2-formyl-3-oxopropanoate, and finally the protecting groups were removed. Results: The purity and yield of regadenoson were improved up to 99.0% and 47.2%, respectively. Conclusion: The improved process can be easily operated with high yield and quality, and is suitable to industrial production.
出处 《上海医药》 CAS 2016年第3期73-75,共3页 Shanghai Medical & Pharmaceutical Journal
关键词 瑞加德松 合成 工艺改进 纯化 regadenoson synthesis process improvement purification
  • 相关文献

参考文献9

  • 1Al Jaroudi W,Iskandrian AE.Regadenoson:a new myocardial stress agent[J].J Am Coll Cardiol,2009,54(13):1123-1130.
  • 2Lieu HD,Shryock JC,von Mering GO,et al.Regadenoson,a selective A2a adenosine receptor agonist,causes dose dependent increases in coronary blood flow velocity in humans[J].J Nucl Cardiol,2007,14(4):514-520.
  • 3Zablocki J,Palle V,Blackburn B,et al.2-Substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2a adenosine receptor[J].Nucleosides Nucleotides Nucleic Acids,2001,20(4-7):343-360.
  • 4Grisenti P,Shahrzad PE,Guazzi G,et al.Stable solid forms of regadenoson:W02014167046AI[P].2014-10-16.
  • 5Linden JM,Sullivan GW,Scheld WM.Method compositions for treating inflammatory response:US6514949[P].2003-02-04.
  • 6Ma C,Nadji S,Wooldridge LT.Improved processes for the preparation of regadenoson and a new crystalline form thereof:W02012149196A1[P].2012-11-02.
  • 7Montgomery JA,Holum LB.Synthesis of potential anticancer agents.Ill.Hydrazino analogs of biologically active purines [J].J Am Chem Soc,1957,79(9):2185-2188.
  • 8Lieu H,Blackburn B,Belardinelli L.Methods and compositions for increasing patient tolerability during myocardial imaging methods:US20090081120A1[P].2009-03-26.
  • 9Kvapil L,Hradil P,Grepl M,et al.Polymorph of 2-[4-[(methylamino)carbonyl]-1 H-pyrazol-1-yl]adenosine:US20140323712A1[P].2014-10-30.

同被引文献17

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部